Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of MG1111 in Healthy Children
NCT03375502Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Nov 2016
- Primary completion
- Jan 2019
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 3 trial of varicella virus vaccine live in varicella (VZV), sponsored by GC Biopharma. Started Nov 2016; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT03375502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375502.